Molecular Partners AG ADR (MOLN)

Nov 13, 2026

Molecular Partners AG announced it will present its latest developments and outlook at the Inaugural UBS Global Biopharma Conference in London on November 16-17, 2026. CEO Patrick Amstutz will present on November 17 at 8 am GMT. The company, a clinical-stage biotech, is developing DARPin therapeutics for cancer patients, focusing on targeted radiotherapeutics.

Oct 31, 2026

Swiss DARPin specialist Molecular Partners is cutting up to 55 jobs, roughly 44% of its workforce, and focusing entirely on radiopharmaceuticals. The company states its cash reserves of CHF 57.5 million will last until the end of 2027, but a recent financial report highlighted "material uncertainty" regarding its ability to continue as a going concern, as it has not secured new funding since October 2024. This strategic shift and downsizing appear to be an effort to preserve funds for its most promising programs, particularly its Radio-DARPin pipeline, which delivers radioactive isotopes to tumor cells.

Oct 30, 2026

Molecular Partners plans to lay off up to 44% of its staff, impacting up to 55 positions, as it shifts its focus and cash reserves towards its radiotherapeutic pipeline, led by the early-phase small cell lung cancer drug candidate, MP0712. The company aims to implement these changes by Q2 2027 and expects to see the full financial effects by the second half of that year. This strategic pivot prioritizes their "Radio-DARPin" therapeutics, with initial safety data for MP0712 expected in December.